Key facts
- This page summarizes Sarah Boyce's Form 4 filing for Avidity Biosciences, Inc. (RNA).
- 8 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2026, 15:19.
Sarah Boyce - 27 Feb 2026 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- RNA
- Reported as of
- 27 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2026, 15:19:36 UTC
- Prior SEC filing
- 26 Feb 2026
- Next SEC filing
- 26 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sarah Boyce filed Form 4 for Avidity Biosciences, Inc. (RNA) on 27 Feb 2026.
Change
- Previous filing in this sequence was filed on 26 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001629383
Primary reporting owner
Boyce Sarah
- Relationship
- President and CEO, Director
- Address
- C/O AVIDITY BIOSCIENCES, INC., 3020 CALLAN RD., SAN DIEGO
- Signature
- /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
- Signature date
- 27 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNA
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -474,861
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -386,015
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 386,015
- Exercise price
- $1.24
- Footnotes
- F2
RNA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -300,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $22.34
- Footnotes
- F2
RNA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -425,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 425,000
- Exercise price
- $14.22
- Footnotes
- F2
RNA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -400,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400,000
- Exercise price
- $22.47
- Footnotes
- F2
RNA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -200,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $6.57
- Footnotes
- F2
RNA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -300,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $10.16
- Footnotes
- F2
RNA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -165,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 165,000
- Exercise price
- $31.42
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Sarah Boyce is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
Footnote F2
The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.